Literature DB >> 9406057

Simultaneous quantitation of specific IgE against 20 purified allergens in allergic patients sera by checkerboard immunoblotting (CBIB).

T Musu1, J Rabillon, C Pelletier, B David, J P Dandeu.   

Abstract

A simple technique, checkerboard immunoblotting (CBIB), is described for simultaneous quantitation of specific IgE antibodies against several allergens in human sera. Using as little as 50 microliters of each of the 20 sera examined against 20 different allergens, it was possible in a single run to achieve 400 tests. To guarantee high specificity and sensitivity of the assay, this new application of CBIB employs purified allergens, cyanogen bromide-activated nitrocellulose membrane, and Phosphorimager technology. Results are expressed both qualitatively (five classes) and quantitatively in kilo units per liter equilibrated against the World Health Organization (WHO) standard for IgE. There was excellent agreement between the results of CBIB and the results of Pharmacia Cap System, an alternative method widely used for measuring serum-specific IgE. The CBIB method certainly could be useful in any laboratory interested in allergy clinical research for easy screening and relative quantitation of allergen-specific human IgE.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9406057      PMCID: PMC6760739     

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  19 in total

1.  Evaluation of a capsulated hydrophilic carrier polymer (the ImmunoCAP) for measurement of specific IgE antibodies.

Authors:  P W Ewan; D Coote
Journal:  Allergy       Date:  1990-01       Impact factor: 13.146

2.  Characterization of Dac g 4, a major basic allergen from Dactylis glomerata pollen.

Authors:  V Leduc-Brodard; F Inacio; M Jaquinod; E Forest; B David; G Peltre
Journal:  J Allergy Clin Immunol       Date:  1996-12       Impact factor: 10.793

3.  Comparison between RAST and Pharmacia CAP system: a new automated specific IgE assay.

Authors:  J Bousquet; P Chanez; I Chanal; F B Michel
Journal:  J Allergy Clin Immunol       Date:  1990-06       Impact factor: 10.793

4.  Cross-antigenicity of horse serum albumin with dog and cat albumins: study of three short peptides with significant inhibitory activity towards specific human IgE and IgG antibodies.

Authors:  H Goubran Botros; C Gregoire; J Rabillon; B David; J P Dandeu
Journal:  Immunology       Date:  1996-07       Impact factor: 7.397

5.  A new multiple specific IgE assay--MAST.

Authors:  J Brostoff; S Pack; T Merrett
Journal:  Lancet       Date:  1984-09-29       Impact factor: 79.321

6.  Allergen nomenclature.

Authors:  T P King; D Hoffman; H Løwenstein; D G Marsh; T A Platts-Mills; W Thomas
Journal:  Allergy       Date:  1995-09       Impact factor: 13.146

7.  Application of checkerboard immunoblotting (CBIB) to the detection of anti-viral IgG in human serum.

Authors:  W Y Craig; S E Poulin; P H Dorsett; T B Ledue; R F Ritchie
Journal:  J Clin Lab Anal       Date:  1993       Impact factor: 2.352

8.  Technical issues related to checkerboard immunoblotting.

Authors:  T B Ledue; W Y Craig; M F Collins; R F Ritchie
Journal:  J Immunol Methods       Date:  1994-12-02       Impact factor: 2.303

9.  Simultaneous determination of total IgE and allergen-specific IgE in serum by the MAST chemiluminescent assay system.

Authors:  C R Brown; K W Higgins; K Frazer; L K Schoelz; J W Dyminski; V A Marinkovich; S P Miller; J F Burd
Journal:  Clin Chem       Date:  1985-09       Impact factor: 8.327

10.  Hydrophobic interaction chromatography for isolation and purification of Equ.cl, the horse major allergen.

Authors:  J P Dandeu; J Rabillon; A Divanovic; A Carmi-Leroy; B David
Journal:  J Chromatogr       Date:  1993-11-17
View more
  1 in total

Review 1.  Microarrayed allergen molecules for the diagnosis of allergic diseases.

Authors:  Adriano Mari; Claudia Alessandri; Maria Livia Bernardi; Rosetta Ferrara; Enrico Scala; Danila Zennaro
Journal:  Curr Allergy Asthma Rep       Date:  2010-09       Impact factor: 4.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.